EGFR and non-small cell lung carcinoma: In November 2015, the U.S. Food and Drug Administration (FDA) approved osimertinib in the form of 80-mg once-daily tablets for the treatment of patients with metastatic NSCLC positive for EGFR T790M (as detected with an FDA-approved test), who had progressed during or after prior EGFR-TKI therapy.